Back to Stories
Ending HIV: Balancing innovation and affordability with lenacapavir
Lenacapavir (LEN), a groundbreaking HIV-1 capsid inhibitor developed by Gilead Sciences, stands on the brink of revolutionizing HIV prevention. As a potential long-acting PrEP option, it could transform the fight against the epidemic. Yet uncertainty surrounds its future pricing and accessibility, raising urgent questions for the communities hardest hit by HIV.
Read the full story here to learn more about the strategies the global community needs to employ now to ensure equitable access to lenacapavir for all.